The effect of the synthetic retinoid etretinate on sputum cytology: results from a randomised trial. by Arnold, A. M. et al.
Br. J. Cancer (1992), 65, 737-743
1992
The effect of the synthetic retinoid etretinate on sputum cytology: results
from a randomised trial
A.M. Arnold"3, G.P. Browmanl3, M.N. Levine"34, T. D'Souza2'3, B. Johnstone'3, P. Skingley3'4,
L. Turner-Smith2, R. Cayco2, L. Booker3, M. Newhouse5 & W.M. Hryniukl"3
'Hamilton Regional Cancer Centre, 2Henderson Hospital, 3McMaster University, 4Ontario Clinical Oncology Group, 'St Joseph's
Hospital, Hamilton, Ontario, Canada.
Summary Laboratory studies, and one previous uncontrolled trial, have suggested that retinoids may reverse
bronchial atypia, a putatively premalignant condition. Sputum sampling is a simple, non-invasive method of
assessing atypia. Smokers with at least a 15 pack-year history were screened for sputum atypia. One hundred
and fifty subjects were randomised to receive the synthetic retinoid etretinate 25 mg orally or identical placebo
daily for 6 months. Compliance was measured by performing pill counts and serum sampling every 2 months
for etretinate levels. The outcomes assessed were, improvements in sputum atypia and toxicity. At baseline
there was no significant difference between the two groups with respect to gender, smoking history or extent of
atypia. Four of 75 subjects on etretinate and six of 75 on placebo dropped out before 6 months. Compliance
as measured by pill counts and etretinate levels was high. Eighty-six per cent of subjects on etretinate took
90% or more of their prescribed medication and etretinate was detected in 245 of 264 samples. By contrast
etretinate was detected in only six of 266 samples in the control group and probably did not represent true
contamination. After 6 months on etretinate there was no difference in the degree of atypia between the two
treatment arms. Toxicity was mild in both groups with considerable placebo effect noted. Etretinate, at the
dose used in this study, had no impact on sputum atypia as detected by sputum sampling.
Despite the recent reduction in the prevalence of smoking in
most Western countries, lung cancer remains a major health
problem and efforts aimed at early detection of lung cancer
in high risk populations have been ineffective in reducing
mortality. While improvements in therapy have occurred,
overall survival for those treated remains poor with very few
patients surviving 5 years from the time of diagnosis. For this
reason, alternative strategies to lung cancer control require
evaluation.
The bronchial epithelium is normally lined by pseudo-
stratified, ciliated, columnar cells. As these cells find their
way into the bronchial secretions, sputum sampling and
cytological examination make it possible to assess changes
which may occur in morphology. Smokers generally show
squamous metaplasia with or without atypical cells in their
sputum. Using well defined criteria, the atypia can be graded
as mild, moderate or severe (Auerbach et al., 1956; Sac-
comanno et al., 1974). The higher grades of atypia are
generally regarded as pre-malignant changes (Auerbach et al.,
1957).
The maintenance of a normal bronchial epithelial pattern
is partially dependent upon vitamin A (Sporn et al., 1986).
Deficiency of the vitamin can cause disappearance of normal
mucous epithelium with replacement by keratinising cells
(squamous metaplasia) (Lippman et al., 1987). In the
laboratory, vitamin A derivatives can inhibit chemically
induced tumorigenesis of the respiratory tract (Saffiotti et al.,
1967). There is also considerable epidemiological data
relating a lower dietary intake or serum levels of retinoids to
a higher incidence of lung cancer (Willett et al., 1984).
Etretinate is a synthetic retinoid used primarily to treat
psoriasis. Koch (1978) has demonstrated its activity against
the premalignant condition of leukoplakia of the oral cavity.
In a small uncontrolled study, Mathe et al. (1982) treated
male subjects, who had squamous metaplasia on bronchial
biopsies, with etretinate 25 mg orally daily. On completion of
6 months of therapy, there was a suggestion of reversal
metaplasia on biopsy for some subjects.
Sputum sampling is in an indirect non-invasive technique
for studying the state of the bronchial mucosa. While it may
be less accurate than direct biopsy the technique has been
used successfully in a study by Heimburger et al. (1988) to
demonstrate the positive effect of vitamin B12 and folate on
subjects with squamous metaplasia. We have identified sub-
jects with bronchial atypia on sputum sampling and have
assessed the effect of a 6 month course of etretinate on
reversing sputum atypia. Compliance was carefully
monitored (Arnold et al., 1990), and the accuracy of the
chosen study endpoint was assessed (Browman et al., 1990).
The study addressed the following questions:
(1) Does administration of the synthetic retinoid, etretinate,
at an oral dose of 25 mg daily, to a group of smokers
with atypia on sputum sampling, produce a clinically
significant reduction in the level of atypia when com-
pared to a placebo?
(2) Are the side-effects of etretinate, at an oral dose of 25 mg
daily, acceptable to this group of participants?
The results are now reported.
Methods
Patient population andscreening phase
Details of the recruitment stage of the study have been
reported previously (Arnold et al., 1989). In brief, inform-
ation about the study was widely disseminated by advertising
locally, using the media and by soliciting direct referrals from
interested physicians. Contacts with at least a 15-pack year
smoking history, and judged potentially suitable, after an
initial phone call, were invited to attend a chemoprevention
clinic run by the Hamilton Regional Cancer Centre or a
satellite clinic at the Toronto-Bayview Regional Cancer Cen-
tre. At the first visit, the outline of the study was explained
and possible side-effects were discussed. Potential partici-
pants, willing to be screened for atypia, and not obviously
excluded by application of initial ineligibility criteria (Table I),
were provided with three sputum jars and instructed on the
technique for production of clean early-morning sputum
samples. They were asked to return to the clinic with three
samples each collected over a 3-day period with each collec-
tion started a week apart. Samples were prepared in the
laboratory and each sample was then screened by two trained
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Table I Ineligibility criteria
Preliminary screen atfirst contact orclinic visit
1. Lessthan 15pack-yearssmokinghistory.
2. Subject is notable toproduce anearlymorning sputumsample.
3. Pneumonia oracute bronchitis within thepast 2months.
4. Clinically significant ischemicheartdisease orpreviouslungcancer.
5. A risk ofpregnancywithin the next 2years, orpresently pregnant.
6. Amedical disorderlikely topreclude safedrugadministration.
7. Subject onlargedoses ofvitamin A.
8. Unable toattend theclinic atspecified intervals for 7months.
9. Women still in thechild-bearing years.
Screen ifsputumsamples metentrycriteria
10. Chest X-ray suspicious forcarcinoma.
11. Cholesterol ortriglycerides outsideacceptable range forageand sex.
12. Unwilling to sign an informed consent.
cytotechnologists (for full details see below). Samples were
graded according to the method of Saccommano et al. (1965)
using the following categories: (i) unsatisfactory specimen; (ii)
satisfactory specimen without metaplasia; (iii) normal meta-
plasia without atypia; (iv) metaplasia with mild atypia; (v)
metaplasia with moderate atypia; (vi) metaplasia with marked
atypia; (vii) malignant cells present. Specimens were con-
sidered unsatisfactory if they: (i) contained inflammatory
elements sufficient to obscure the cells to be examined; (ii)
contained epithelial cells thought to be affected by an
inflammatory process or (iii) contained no alveolar macro-
phages, indicating that the specimen was not from the lower
respiratory tract. Subjects producing one or more unsatisfac-
tory samples were asked to provide repeat samples. Speci-
mens in which there were disagreements between observers
were submitted to a consultant cytopathologist for adjudica-
tion (T D'S).
Ifatypia, as specified in Table II, was present and potential
participants were not excluded on the basis of significantly
elevated triglycerides, cholesterol, liver or renal function tests,
or abnormal chest X-ray suggestive of overt malignancy, they
were eligible for study entry and were asked to give informed
consent. It should be noted that those included as mild
atypia had to have at least two out of their three screening
samples graded as mild. Those included as moderate and
severe atypia were graded on the basis of the highest grade of
the three satisfactory screening samples.
The study received ethical approval from the participating
institutions and informed consent was obtained on all study
participants.
Intervention
Eligible subjects were stratified by gender, degree of atypia
(mild vs moderate and severe) and location (Hamilton Centre
vs Toronto Bayview Centre). Participants were randomly
allocated to receive either etretinate, 25 mg orally daily, or an
identical placebo (supplied by Hoffmann-La Roche, Missis-
sauga, Canada), for a 6 month period. Dose reductions were
made for toxicity as follows (see subsequent section for
definitions of toxicity) (i) for mild toxicity no reduction was
made; (ii) for moderate toxicity the dose was reduced to
25 mg alternate days, for an initial period of 2 weeks, and
subsequently escalated if possible; (iii) for severe toxicity, the
drug was temporarily or permanently withdrawn.
Follow-up studies
Follow-up visitors were scheduled at 2, 4, 8, 16 and 24 weeks
after randomisation. At each visit a toxicity questionnaire
was administered and blood was taken for liver function
tests, fasting triglycerides and cholesterol. Three-day, follow-
up sputumn samples were collected monthly at 4, 8, 12, 16,
20 and 24 weeks. For the first half of the study, during the
follow-up phase only one, three-day sample was collected
each month. After the publication of a study by Heimburger
et al. (1988), which had a design very similar to the present
trial, we adopted a policy of collecting three, 3-day samples
at weeks 24, 25 and 26 to allow a more direct comparison
with the three samples collected during the screening phase.
Encouraging andmonitoring compliance
Volunteers were not financially rewarded, however, to
encourage participation and compliance, the clinic was run to
reflect the needs of a well, predominantly employed, popula-
tion. Timing of visits was flexible within the constraints of
adhering to the overall protocol. Participants were re-
imbursed for out-of-pocket expenses such as travel and park-
ing. Those fasting to provide triglyceride and cholesterol
levels were offered breakfast vouchers following blood samp-
ling.
Compliance in taking the study medication was monitored
by performing pill counts at weeks 8, 16 and 24 and by
serum sampling for etretinate levels at weeks 4, 8, 16 and 24.
Compliance, as assessed by pill counts, was calculated using
the actual vs the expected pills remaining, taking into account
authorised dose reductions and/or altered visit times. The
results were expressed as the proportions of subjects taking
more than 80% or more than 90% of their expected medica-
tion. Compliance with respect to timely follow-up visits and
return of sputum samples was assessed at the half-way point
of the trial and proved satisfactory. (Arnold et al., 1990).
Samples from both subjects on etretinate and placebo were
tested. Blood was collected in black-coated tubes under
vacuum and was allowed to clot. The serum was removed
and placed into coated glass tubes and stored at - 20°C. To
prevent degradation of the light sensitive retinoids all proce-
dures were performed under subdued light. Etretinate was
measured by high-pressure liquid chromatography (HPLC)
according to the method of McLean et al. and modified in
our laboratory as previously published (McClean et al.,
1982; Browman et al., 1989). Serum samples were ordered
randomly, coded, and the HPLC chromatograms were inter-
preted by a technologist who was unaware of the timing of
each sample or of the treatment allocation.
Outcome assessment
Following randomisation, both the study subjects and nurses
were blinded to the treatment allocation and the results of
the monthly follow-up sputum collections. The study
cytotechnologists and pathologist were blinded to the treat-
ment allocation. The follow-up slides were read in random
order using the same six category diagnostic scale as in the
screening phase. The final diagnosis for each month was
coded and sent to the study data manager to be entered in
the subject's record and study database.
Response to the study intervention was assessed using the
last satisfactory sputum sample obtained after 6 months on
treatment (if a sample, at month 6, was unsatisfactory the
last satisfactory sample from previous months was used to
assess outcome for that subject). The criteria for improve-
ment were as follows: (i) for subjects, initially diagnosed as
moderate or severe atypia, a response was to be at least a
two category downward grade in sputum diagnosis and (ii)
for subjects, initially diagnosed as mild atypia, the sputum
had to be classified as at least no atypia (with or without
squamous metaplasia). In addition, the overall distribution of
sputum grades on completion was compared between the two
treatment groups.
For potential symptoms attributable to treatment, toxicity
was scored on a questionnaire, administered by the study
nurse, using an eight point scale with a score of eight
Table II Eligibility criteria
Current smokers with thefollowing:
1. At least two ofthree satisfactory sputum samples showingmild
atypia
or
2. At least one ofthree satisfactory sputum samples showing
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representing complete absence of a particular symptom. A
score of seven, six or five represented mild toxicity, a score of
four or three represented moderate toxicity and scores of two
or one were regarded as severe toxicity. The toxicity score
formed the basis for the dose reductions (see above).
Sputum sample preparation and reading
Each sputum sample was submitted as a deep-cough speci-
men, collected daily for 3 consecutive days. Each 3-day colec-
tion was pooled and constitutes a single specimen. Specimens
were fixed and prepared according to the method of Saccom-
mano et al. (1965) and stained using the Papanicolaou tech-
nique (Papanicolaou, 1954). The sputum samples were
prepared on glass slides which were coded and ordered ran-
domly. Six slides were prepared per specimen. During both
the screening and post randomisation phases of the study,
two cytotechnologists prospectively and independently
recorded the diagnosis using all six slides on each specimen
submitted. All observers were appropriately trained and
registered cytotechnologists. As part of the quality control
built into the study, observations concerning observer varia-
tion of sputum cytodiagnosis were made at the half way
point of the trial and the resuls have been published
previously (Browman et al., 1990).
Statistical considerations and study conduct
The sample size calculation was based upon the proportion
of subjects, on active treatment, showing a response to treat-
ment. We wished to be able to detect an overall response rate
of 25% in the active treatment group and to demonstrate this
difference with a = 0.05 (one-sided). In addition, we wished
to detect the specified difference with a power of 90%. This
gave an initial sample size of 106 subjects. At the outset of
the study, we determined to examine subject compliance and
to test the reliability of the chosen study endpoint (i.e.
sputum atypia) at the half-way point of the trial and to make
adjustments as necessary. Our observations have already
been published. As a consequence, of these findings, the final
sample size was adjusted upward to 150 subjects allowing us
to carry out some subgroup analyses without significant loss
of power.
The proportion of responders, in the two treatment
groups, was compared using the Fisher's exact test. Toxicity,
in the two treatment groups, was compared using an analysis
of variance and covariance with repeated measures.
Results
Patient population
Between October 1986 and December 1989, 150 subjects were
randomised into the study. These subjects were recruited
from a total potential particpant pool of 2,223 subjects who
made an initial contact with one of the two clinics. Of this
potential participant pool, 1,204 were not invited to attend
the clinic, usually because they were obviously excluded on
the basis of age, gender, inadequate smoking history or
misinterpreting the purpose of the study. Four hundred and
twenty-one subjects were eventually asked to provide sputum
samples, but 123 subjects did not return at least three satis-
factory samples. Of the 298 subjects who provided three
satisfactory sputum samples, 229 (77%) demonstrated
sufficient atypia to meet the inclusion criteria but a further 79
were subsequently excluded. The most common reasons for
these exclusions were: (i) abnormal liver function, fasting
lipids or chest X-ray (33 subjects); (ii) unwillingness to attend
the clinic for a further 6 months (21 subjects); (iii) medical
disorder thought to preclude safe drug administration (ten
subjects); (iv) refusal to provide informed consent (five sub-
jects).
The distribution of baseline characteristics of the 150 ran-
domised subjects is shown in Table III. Seventy-five subjects
Table III Baseline characteristics and subject disposition on
completion of 6 months
Etretinate Placebo
(n = 75) (n = 75)
At baseline
Age (years) 50.8 (10) 52 (9.5)
Mean (s.d.)
Gender
Female (%) 27 (36) 28 (37)
Male (%) 48 (64) 47 (63)
Pack years
Mean (s.d.) 52 (29.5) 49 (23.4)
Atypia
Mild (%) 21 (28.0) 19 (25.3)
Moderate (%) 52 (69.3) 56 (74.7)
Severe (%) 2 (2.7) 0
After 6 months
Dropped out (%) 4 (5) 6 (8)
Required dose reduction (%) 16 (21) 18 (24)
were randomised to each arm. There is no significant differ-
ence in the mean distribution of age, gender, number of pack
years smoked and grade of atypia on the three screening
sputum samples. Subjects who subsequently dropped out of
the study and those requiring a dose reduction are also
shown in Table III. Seventy-one of 75 subjects, on active
treatment, and 69 of 75 subjects, on placebo, completed the 6
month follow-up period. Two of the subjects, on placebo,
were not able to provide satisfactory sputum samples for the
final analysis and were thus excluded from response assess-
ment but were included in the assessment of toxicity. Fifty-
nine subjects on active treatment and 57 on placebo
completed the 6 month study period without requiring a dose
reduction.
Compliance
Compliance was monitored by pill counts and by serum
sampling for etretinate levels. As monitored by pill counting
(Table IV), compliance was slightly lower for those on active
drug, but the differences were not significant. Overall 530
blood samples for serum etretinate levels were obtained and
successfully analysed from subjects on active drug or placebo.
Etretinate was detected in 245 of 264 (92.8%) samples of
subjects on active drug and in only six of 266 (2.3%) of those
on placebo. Of the 36 missing samples for subjects on active
treatment, 14 could be attributed to the four subjects who
dropped out of the study. The other missing samples were
attributed to missed visits (3) and lost or spoiled samples
(16). Each of the six positive samples, from those on placebo,
came from different subjects suggesting that this was not true
contamination but either an error during the assay procedure
or due to switched samples. Compliance, as measured by
serum sampling, was thus very high and contamination in the
control group was negligible. The mean etretinate levels for
each sampling time are shown in Figure 1. The consistent
levels of etretinate also suggest that compliance, with the
study medication, did not fall off significantly during the 6
month treatment period.
Results ofsputum cytology
One hundred and thirty-eight subjects completed the study
and were able to provide satisfactory sputum samples for the
final analysis. The overall distribution of sputum grades on
the initial sputum screen and on the last satisfactory sample
obtained after 6 months of treatment are shown in Figure 2.
Comparing the pre and post-treatment distributions, an
overall reduction in atypia is seen but the final distribution is
virtually identical for both groups.
Using the response criteria, the number of subjects show-
ing an improvement in sputum cytology, compared to the740 A.M. ARNOLD et al.
Table IV Subject compliance by study group
After 6 months Etretinate Placebo
Pill counts
>80% of pills taken 95.5% 100%
>90% of pills taken 86.6% 93.3%
Serum sampling
Etretinate detected 245 6
Etretinate not detected 19 260
Weeks post randomization
Figure 1 Serum etretinate levels for subjects on active treatment.
Table V Subjects showing improvement in sputum atypia by study
group
(a) All Subjects
Etretinate Placebo
initial screen, is shown in Table Va. Improvement was noted
in 43 of 138 (31.2%) subjects; 23 of 71 (32.4%) on etretinate
and 20 of 67 (29.8%) on placebo. The small difference noted
between the two treatment groups was not statistically
significant. A subset analysis of only subjects with moderate
or severe atypia is shown in Table Vb. The number of
subjects responding in each group (16) was identical.
Further subset analyses were carried out as follows: (i) on
those subjects completing the study without dose reduction;
(ii) on the proportion of subjects showing only a one
category change in sputum (i.e. less than a complete response
to therapy) and (iii) on subjects in the latter half of the study,
comparing the worst grade of the three samples collected at
month 6 with the three screening samples. Again the response
rates and, overall distributions of atypia, were identical in
both groups (results available but not shown).
Toxicity
Toxicity is shown in Table VI. The only symptoms showing a
statistically significant difference between active treatment
and placebo were dry lips (mean score 5.6 vs 7; P = <0.0001)
and dry mouth (mean score 6.0 vs 7.0; P = 0.006). For
several other symptoms (dry skin, itching and hair loss) there
was a trend towards a mildly toxic effect of etretinate, but
the differences did not reach statistical significance. On com-
pletion of 6 months, when compared to the baseline levels,
Etretinate
screening
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Fisher's exact P = 0.45
(b) Subjects with moderate or severe atypia only
Etretinate
Improvement
No improvement
Totals
Placebo
16 16
34 37
50 53
Fisher's exact P = 0.51
both cholesterol and triglycerides showed a slight rise in the
treatment group compared to a slight fall in the control
group but the differences were not statistically significant.
The numbers of subjects requiring dose reductions for
presumed toxicity is shown in Table III. Subjects were
equally distributed in both treatment and control groups (16
and 18 respectively), suggesting that 'true' drug toxicity was
not responsible for the majority of dose reductions.
Discussion
There have been some encouraging trends towards tobacco-
free societies, in most Western countries however, even when
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Figure 2 Distribution of sputum atypia at time of screening and after completion of treatment with etretinate or placebo.
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Table VI Toxicity, after 6 months, by study group
Meansymptomscoreat6monthsa (s.d.)
Etretinate Placebo P
Dry lips 5.6 (2.3) 7.0 (1.0) <0.0001
Dry mouth 6.0 (2.0) 7.0 (1.3) 0.006
Dry skin 6.7 (1.9) 7.3 (1.5) 0.16
Nail problems 7.1 (1.7) 7.3 (1.5) 0.84
Itchiness 7.0 (1.8) 7.4 (1.2) 0.26
Sweating 7.3 (1.5) 7.4 (1.2) 0.88
Hair loss 6.9 (1.6) 7.3 (1.3) 0.06
Nose bleeds 7.7 (1.1) 7.7 (0.6) 1.0
Bruising 7.5 (1.0) 7.7 (0.9) 0.71
Appetite change 7.8 (0.4) 7.7 (0.7) 0.53
Headaches 7.2 (1.5) 7.3 (1.5) 0.33
Tiredness 6.2 (2.0) 6.3 (1.8) 0.93
Mean lipidchangeftom baseline at6months (s.d.)
Etretinate Placebo P
Cholesterol 0.06 (0.57) - 0.06 (0.60) 0.07
Triglycerides 0.13 (0.49) - 0.62 (6.50) 0.29
aMaximum possible score = 8 (complete absence of symptoms).
fully aware of the risk of lung cancer, many addicted
smokers are unable to quit despite repeated efforts. Thus
alternative strategies to lung cancer control are being ex-
plored.
One major area of research is chemoprevention. Many
studies are in progress, however before committing more
resources to long-term chemoprevention studies, some indica-
tion of treatment efficacy is desirable. The use of an
intermediate biological endpoint, in a chemoprevention trial,
can lead to a much reduced sample size and a positive result
would provide a basis for testing an active drug in larger
studies using cancer incidence as the final endpoint. Based
upon the activity of the synthetic vitamin A analogue
etretinate and other retinoids against the premalignant condi-
tion of oral leukoplakia (Koch, 1978) and a previous
positive, but uncontrolled trial, in subjects with squamous
metaplasia of the tracheobronchial tree (Mathe et al., 1982),
the hypothesis being tested, in this study, was that etretinate
might reverse bronchial atypia. If effective the intervention
would be relatively easy to apply and sputum sampling for
atypia is a widely available, acceptable, non-invasive tech-
nique which could be applied to the majority of heavy
smokers.
In our trial, on completion of 6 months of treatment with
etretinate or placebo the sputum results were analysed: (i) by
comparing the distribution of sputum grades, in the last
samples obtained; (ii) using strict intrasubject response
criteria and (iii) by performing subset analyses on subjects
most likely to show a possible treatment effect. In both
groups we observed a reduction in the extent of atypia. As a
final single sputum result was being compared to the results
of three initial screening samples, the improvement observed
in both groups, was expected and is a sampling artifact and
to some extent due to natural regression towards the mean.
The important observation is that, however analysed, no
significant differences were detected, between the two treat-
ment groups, and the most obvious conclusion to be drawn
from the results presented here, is that etretinate, at this
dose, has no impact on sputum atypia.
These results are thus a contradiction of the previous study
by Mathe et al. (1982) in which etretinate was given, at the
same dose and for the same duration as in the present study.
Mathe's study differed primarily from our study in that it
was uncontrolled. However, his study also used a different
tissue sampling technique. Mathe reported that 20 of 30
subjects showed an improvement in an index ofatypia derived
from pathological examination ofbronchoscopically obtained
biopsy specimens, however, it is not stated whether the final
biopsies were read by observers who were blinded to the
initial diagnosis. Thus the results could have been influenced
by bias. We employed a rigorous placebo-controlled design
with close attention to blinding of both subjects and study
personnel and could not detect any effect of the etretinate.
The divergent results could be possible for a number of
reasons.
It is possible that direct sampling of the bronchial tree, is a
more accurate reflection of specific changes than sputum
sampling as the latter technique does not allow localisation
of sites of atypia. It should also be noted that Mathe et al.
used metaplasia as an entry criterion while the present study
required, as an entry criterion, squamous metaplasia together
with atypia. Thus Mathe's trial may have included more
subjects with a lesser degree of abnormality. It is thus con-
ceivable that etretinate influences simple metaplasia but not
the more abnormal condition of metaplasia combined with
atypia.
It is also possible that observer variation of sputum
cytodiagnosis may have masked a true treatment effect due
to etretinate. As part of the quality control measure built
into our study, we carried out an evaluation of observer
variation on sputum samples, collected during the screening
phase of this study. The results of this evaluation have
already been published (Browman et al., 1990). Complete
agreement between the two primary observers, on 300 speci-
mens from 130 subjects, was 68% (kappa = 0.58). Of the 96
disagreements, only 17 were of more than one category in the
six category classification. As the majority of subjects (those
with moderate or severe atypia) were required to improve by
two categories to be regarded as responders observer mis-
classification is not likely to have had a large impact in our
study.
Repeated bronchial biopsies are not likely to be feasible in
a general population of smokers and other investigators have
attempted to use repeated sputum sampling. In an uncon-
trolled study, Saccomanno et al. (1982) identified a group of
16 subjects with either moderate or severe atypia. All had
confirmatory repeat sputum sampling prior to initiation of
therapy. The subjects were given 13-cis retinoic acid in a dose
of 0.5-3 mg kg-' for up to 6 months. On completion of this
study, no significant improvement (or deterioration) was
noted in the level or degree of atypia. The observation was
made that degenerative alterations were seen in many cells
but the significance of this finding is unclear. The small
numbers studied, the lack of a control group, and the widely
varying drug dosages used make any further interpretation
difficult. Heimburger et al. (1988) randomised subjects with
squamous metaplasia to receive both vitamin B12 and folate
or placebos. Complete interobserver agreement was obtained
in only 22 of 40 specimens (55%). Despite the variability,
observed in that trial, and a smaller sample size than in the
present report, there was sufficient power to detect a bene-
ficial effect of administration of vitamin B,2 and folate in the
treatment group, compared with the group on placebo. The
performance of the cytotechnologists, in our study was
superior to that of Heimburger et al. and it is unlikely
therefore, that inaccurrate sputum cytodiagnosis significantly
affected the outcome, as there is not even a slight trend, in
favour of the active treatment arm.
Heimburger's study is also difficult to compare with the
present report due to different proportion of subjects with
more severe grades of atypia. Only eight of 73 (10.9%)
subjects entered in Heimburger's trial had moderate or severe
atypia while in our study 110 of 150 (73%) had moderate or
severe atypia at the time of study entry. Although the drugs
studied differed, this lends some further support to the
hypothesis that an effective chemopreventive intervention
may only affect earlier stages of squamous metaplasia but
this remains to be tested in subsequent trials.
Zelen (1988) has pointed out the detrimental effect of poor
compliance on the statistical efficiency of chemoprevention
studies. At the outset of our study we determined to examine
several aspects ofcompliance at the halfway point of the trial
and to make an appropriate adjustment in sample size if
necessary. The results of these observations have been
previously published in detail (Browman et al., 1989; Arnold
et al., 1990). In brief, 88% follow-up visits occurred on
schedule with only nine missed visits of a possible total of742 A.M. ARNOLD et al.
380. Of 456 possible sputum samples expected to be returned
443 (97.1%) were actually returned on time. Serum sampling
for etretinate levels and pill counts suggested that poor com-
pliance would not be an important issue however a small
upwards adjustment of sample size was made at this point.
On completion of the study the updated results show that
compliance remained high as monitored by pill counts and
serum sampling. Compliance was higher than in a recently
published chemoprevention study by Greenberg et al.
(Greenberg et al., 1990) which tested beta-carotene to try and
prevent recurrence of basal-cell and squamous cell cancers of
the skin. Nevertheless previous studies have shown that pill
counts, used alone, to monitor compliance, have been un-
reliable when checked by biochemical monitoring for drug or
metabolite (Bergman & Werner, 1963). This was not our
experience as the information obtained from pill counts has
been strongly supported by the measurement of etretinate
levels. Due to the prolonged half-life of etretinate, it is not
possible to assess whether subjects omitted to take pills but the
stable levels of etretinate, with each visit, certainly suggest that
this was not a significant problem. Thus the proportion of
subjects who were non-compliant and the low degree of con-
tamination noted in the placebo arm are unlikely to have
significantly affected the overall outcome.
A formal run-in period, using placbeo, to exclude non com-
pliant subjects was not part of our study design, however, those
less motivated were unlikely to complete the stages leading to
eventual study entry (Arnold et al., 1989). In addition, close
attention to detail and a considerable effort to accommodate
to the varying schedules of participants contributed to achiev-
ing a very high degree of subject compliance (Haynes, 1979).
Toxicity, in this study, was very mild. Furthermore, the
observation that the number of subjects requiring dose reduc-
tions for toxicity and the number of subjects dropping out
were equally distributed between treatment and control arms
suggests that the blinding of both subjects and study personnel
was effective. The dose reductions, which were required,
appear to reflect more an apparent true placebo effect rather
than significant toxicity. The dose of etretinate we chose,
25 mg orally daily, was the same as that used by Mathe et al.,
however the lack of major toxicity may indicate that this dose
was too low to effect a change on sputum atypia. The issue of
dose intensity of retinoid chemoprevention has been discussed
by Band et al. (1989). In experimental systems, pharmacologic
doses of retinoids have been needed to inhibit tumour develop-
ment (Crocker & Sanders, 1970). Etretinate is used primarily
to treat psoriasis in doses up to 100 mg daily. At this higher
dose, side-effects from etretinate can be significant. If a
strategy using chemoprevention is to ultimately impact on lung
cancer incidence it is very unlikely that any but minor side-
effects would be acceptable to an essentially healthy popula-
tion of smokers. Nevertheless, it is feasible that higher doses of
etretinate, than used in this study, may have an impact on
sputum atypia, but this remains to be tested.
The use of pharmacological interventions to prevent cancer
in subjects known to be at high risk is still experimental
(Meyskens, 1990; Boone et al., 1990) and some negative
studies are likely. However, investigators have reported
preliminary encouraging results from carefully designed con-
trolled trials. Heimburger et al. (1988) have demonstrated the
efficacy of vitamin B12 and folate in a study very similar to the
present one. In a series of studies, Hong et al. (Hong & Doos,
1985; Hong et al., 1986) have demonstrated that the retinoid
13-cis-retinoic acid (isotretinoin) is active in reversing the
premalignant condition of leukoplakia and more recently have
demonstrated that the drug can prevent the occurrence of
second primary malignancies in patients treated for primary
tumours of the head and neck (Hong et al., 1990). In a non
randomised comparison, etretinate was equally effective as
13-cis-retinoic acid against leukoplakia (Koch, 1978). Clearly
retinoids, including etretinate, can be effective in reversing
some of the carcinogenic changes related to smoking. Hong
cites the observation that field concerisation exposes wide
areas of epithelial surface to carcinogenic insult. Effective
pharmacological agents thus have the potential to reverse or
delay development of cancers of several related sites and the
continued search for effective agents remains important.
There are several large randomised trials using retinoids or
beta-carotene attempting to reduce cancer incidence in volun-
teer smokers. These studies require enormous resources and
will take many years to complete. Our study was an attempt to
obtain further biological information on the short-term impact
of a retinoid on the intermediate biological endpoint of
sputum atypia. The negative result should not discourage other
investigators from carrying out similar studies using inter-
mediate endpoints, however, changes in sputum cytology alone
may not be sensitive or precise enough. Other studies, present-
ly in progress, or being planned, use bronchial biopsies and
squamous cell differentiation markers, such as transgluta-
minase type I, involucrin and the high molecular weight KI
keratin as study endpoints and may provide more useful in-
formation in the future (Lippman et al., 1990).
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